Physician profile
Nicholas Cunningham
NPI 1649928698
$2,814.84
in general payments reported to CMS, 2019-2025
20 companies · $912 in 2025
The $912 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $615 · 2023: $936 · 2024: $352 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,080 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.30 |
| Education | $119.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $353.45 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $339.53 | 2022-2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $339.11 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $250.07 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $229.04 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $206.27 | 2022-2024 | Trintellix |
| Abbvie INC. | $181.22 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $170.63 | 2022-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $156.93 | 2022-2024 | Quviviq |
| Corium, LLC | $122.60 | 2022-2024 | Azstarys, Azstarys |
| Alkermes, INC. | $122.24 | 2022-2024 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $84.84 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $61.02 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $55.57 | 2022-2023 | Jornay Pm |
| Lundbeck LLC | $39.26 | 2022-2025 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $25.74 | 2025 | Fanapt |
| Tris Pharma INC | $21.19 | 2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $20.60 | 2024 | Adzenys Xr-Odt |
| Luye Pharma (USA) LTD. | $20.22 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $15.31 | 2023 | Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.